Tuesday, 02 January 2024 12:17 GMT

Walgreens Plans to Sell Abortion Pill Where Legally Permissible, Faces Backlash from California Governor


(MENAFN) Walgreens has stated that it intends to sell the abortion pill, mifepristone, in jurisdictions where it is legally permitted to do so. The company plans to become certified by the Food and Drug Administration (FDA) to dispense the medication, in compliance with federal and state regulations. The FDA recently authorized retail pharmacies to sell mifepristone, subject to the agency's monitoring program, which regulates the medication's distribution and usage.

However, Walgreens' decision to sell mifepristone has raised concerns among Republican attorneys general in several states, who have warned the company against selling or mailing the medication in their jurisdictions. In response to this, California Governor Gavin Newsom announced on Monday that the state would cease doing business with Walgreens. He accused the company of "caving to right-wing bullies pushing their extremist agenda" and prioritizing politics over women's and girls' health. Newsom's spokesperson indicated that the state would review all relationships between Walgreens and California.

Walgreens has clarified that it plans to sell mifepristone only where it is legal to do so under state and federal law. The company has not specified which states it intends to sell the medication in, but it has expressed a commitment to ensuring that its dispensation of mifepristone is consistent with relevant regulations. Walgreens' decision to sell the abortion pill has sparked a debate around the role of private corporations in reproductive healthcare and the rights of individuals to access essential medical services.

MENAFN08032023000045012476ID1105731425



Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.